Recap 2023: From postpartum depression to Alzheimer’s disease, here are some crucial USFDA approvals this year

Elevating Patient Care: Top 10 FDA-Approved Drugs in 2023

The United States Food and Drug Administration (FDA) stands at the forefront of approving innovative drugs and products that significantly impact patient outcomes. In 2023, a total of 55 novel drugs have received FDA approval, spanning various medical conditions from Alzheimer’s disease to cancer, migraines, menopausal symptoms, and post-partum depression. Here, we highlight the top 10 drugs set to play a crucial role in patient care and treatment:

1. ORSERDU (elacestrant): Approved for advanced metastatic breast cancer, ORSERDU is a selective oestrogen receptor degrader (SERD) marketed by Stemline Therapeutics.
2. ZURZUVAE (zuranolone): Addressing postpartum depression, ZURZUVAE is a gamma-aminobutyric acid (GABA) positive allosteric modulator developed by Sage Therapeutics and Biogen.
3. VEOZAH (fezolinetant): Designed for managing menopausal hot flushes, VEOZAH is a neurokinin (NK) 3 antagonist marketed by Astellas Pharma.
4. ZAVZPRET (zavegepant): Approved for migraine treatment, ZAVZPRET is a calcitonin gene-related peptide (CGRP) antagonist nasal spray developed by Pfizer in collaboration with Bristol Myers Squibb.
5. VOWST (fecal microbiota spores): Targeting recurrent Clostridioides difficile infection, VOWST is a microbiome modulator developed by Seres Therapeutics and marketed by Nestlé.
6. LEQEMBI (lecanemab): A breakthrough in Alzheimer’s treatment, LEQEMBI is an anti-beta-amyloid (Abeta) protofibrils mAb marketed by Eisai.
7. SKYCLARYS (omaveloxolone): Approved for Friedreich’s ataxia, SKYCLARYS is a nuclear factor erythroid-derived 2 (Nrf2) activator developed by Reata Pharmaceuticals.
8. ELEVIDYS (delandistrogene moxeparvovec): Targeting Duchenne muscular dystrophy, ELEVIDYS is a micro-dystrophin gene therapy marketed by Sarepta Therapeutics.
9. POMBILITI (cipaglucosidase alfa): Treating Pompe disease, POMBILITI, approved in September, is distributed and marketed by Amicus Therapeutics.
10. NARCAN NASAL SPRAY (naloxone hydrochloride): Approved for over-the-counter use in treating opioid overdose, NARCAN NASAL SPRAY provides a critical solution for emergency situations.

These groundbreaking drugs showcase the relentless pursuit of medical advancements, offering hope and improved treatment options for patients. As the healthcare landscape evolves, these FDA-approved drugs contribute significantly to enhancing the quality of patient care.